Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.
OBJECTIVE
Cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory and cardiovascular disorders. Their actions are mediated by CysLT(1) and CysLT(2) receptors. Here we report the discovery of 3-({[(1S,3S)-3-carboxycyclohexyl]amino}carbonyl)-4-(3-{4-[4-(cyclo-hexyloxy)butoxy]phenyl}propoxy) benzoic acid (HAMI3379), the first potent and selective CysLT(2) receptor antagonist.


METHODS
Pharmacological characterization of HAMI3379 was performed using stably transfected CysLT(1) and CysLT(2) receptor cell lines, and isolated, Langendorff-perfused, guinea pig hearts.


RESULTS
In a CysLT(2) receptor reporter cell line, HAMI3379 antagonized leukotriene D(4)- (LTD(4)-) and leukotriene C(4)- (LTC(4)-) induced intracellular calcium mobilization with IC(50) values of 3.8 nM and 4.4 nM respectively. In contrast, HAMI3379 exhibited very low potency on a recombinant CysLT(1) receptor cell line (IC(50) > 10 000 nM). In addition, HAMI3379 did not exhibit any agonistic activity on both CysLT receptor cell lines. In binding studies using membranes from the CysLT(2) and CysLT(1) receptor cell lines, HAMI3379 inhibited [(3)H]-LTD(4) binding with IC(50) values of 38 nM and >10 000 nM respectively. In isolated Langendorff-perfused guinea pig hearts HAMI3379 concentration-dependently inhibited and reversed the LTC(4)-induced perfusion pressure increase and contractility decrease. The selective CysLT(1) receptor antagonist zafirlukast was found to be inactive in this experimental setting.


CONCLUSIONS
HAMI3379 was identified as a potent and selective CysLT(2) receptor antagonist, which was devoid of CysLT receptor agonism. Using this compound, we showed that the cardiac effects of CysLTs are predominantly mediated by the CysLT(2) receptor.
Wunder
F
F
Bayer Schering Pharma AG, Wuppertal, Germany. frank.wunder@bayerhealthcare.com <frank.wunder@bayerhealthcare.com>
Tinel
H
H
Kast
R
R
Geerts
A
A
Becker
E M
EM
Kolkhof
P
P
Hütter
J
J
Ergüden
J
J
Härter
M
M
D000818:Animals; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006801:Humans; D007211:Indoles; D020128:Inhibitory Concentration 50; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D017997:Leukotriene C4 / Q000378:metabolism; D017998:Leukotriene D4 / Q000378:metabolism; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D048448:Phenylcarbamates; D010795:Phthalic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D011485:Protein Binding; D018077:Receptors, Leukotriene / Q000187:drug effects* / Q000378:metabolism; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000494:pharmacology
C549635:3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-(cyclohexyloxy)butoxy)phenyl)propoxy)benzoic acid; D003509:Cyclohexanecarboxylic Acids; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D010795:Phthalic Acids; D018077:Receptors, Leukotriene; D013449:Sulfonamides; D014105:Tosyl Compounds; D017997:Leukotriene C4; D017998:Leukotriene D4; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor; D002118:Calcium; C062735:zafirlukast